Opexa Therapeutics Reveals Steady Progress Of Phase IIb Trial Of Tovaxin And Recommendation Of Data Safety Monitoring Board - Quick Facts
Tuesday, September 11, 2007; Posted: 07:48 AM
(RTTNews) - Opexa Therapeutics, Inc. (OPXA | charts | news | PowerRating) on Tuesday revealed additional details on its 150-patient Phase IIb safety and efficacy study or TERMS study of Tovaxin in multiple sclerosis.
In the multicenter, randomized, double blind, placebo-controlled TERMS study all 150 patients have received their first vaccine dose in the five dose vaccine series and more than 60% of the total 750 vaccine doses of the study have been delivered, the company said.
In addition, the company noted that the Data Safety Monitoring Board has met three times and reported no safety issues and recommends continuing the trial as planned.
Commenting on the recent highlights of the trial, the company's president and chief executive officer, David McWilliams said, "We are encouraged that the diverse myelin peptide reactive profile of each patient that we have identified thus far in the study brings us closer to realizing the promise of individual therapy in general, and specifically supports our individualized therapy approach to the treatment of multiple sclerosis."